Delivery Order SPE2DB24D1201-SPE2DB25FJDST
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (30-count supply) with a ceiling value of $1,553.40. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and has an ultimate completion date of August 18, 2025. The delivery order is being performed from AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is a child contract issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,370.76 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100 count) on July 31, 2025, with completion scheduled for August 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place...
- The Defense Logistics Agency awarded a $1,288.86 delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Envarsus XR 1 mg tablets (100-count package), with an ultimate completion date of August 12, 2025. This firm fixed-price contract, which carries no set-aside designation, represents a competitively awarded delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the federal government. The product will be delivered to the company's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Envarsus XR 1 mg tablets (100-count packaging). This firm fixed price delivery order, valued at $2,148.10, is scheduled for completion by August 18, 2025, and represents a non-set-aside, competitively awarded contract. The delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Envarsus XR 4 mg tablets (100 count) with a contract value of $1,711.95. This firm fixed price delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,216.11, is for the supply of Envarsus XR 1 MG tablets. This order is placed under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC covers a comprehensive range of...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,718.48 for 100 tablets of Envarsus XR 1 mg on July 28, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price, competitively awarded contract involves pharmaceutical delivery to support federal medical procurement needs. The contract does not include a set-aside designation and is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a $1,711.95 delivery order to AmerisourceBergen Drug Corp for 100 tablets of Envarsus XR 4 mg on July 31, 2025, with an ultimate completion date of August 21, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order for pharmaceutical supply to support federal medical procurement needs. The contract was executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $1,711.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Envarsus XR 4 mg tablets (100-count units) with an ultimate completion date of August 14, 2025. This non-set-aside competitive award was issued on July 24, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,288.86 to AmerisourceBergen Drug Corp for Envarsus XR 1 mg tablets (100 count), with an ultimate completion date of August 20, 2025. This non-set-aside, firm fixed-price delivery order was competitively awarded and represents a continuation of the contractor's pharmaceutical supply activities supporting federal medical procurement. The work will be performed at AmerisourceBergen Drug Corp's corporate office location in...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDSTDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Envarsus XR 1 mg tablets (100-count units) with a contract ceiling value of $1,288.86. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award utilized no set-aside designation and was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across military and veteran healthcare systems. The company's DLA pharmaceutical prime vendor contract enables it to supply a comprehensive range of medical commodities including specialty medications, brand-name and generic drugs, vaccines, and related medical supplies to support defense health operations globally. This delivery order for Envarsus XR—an immunosuppressant medication—exemplifies the company's role in fulfilling routine pharmaceutical supply requirements for federal healthcare programs through the Defense Logistics Agency's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/31/25 |